{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:37:58Z","timestamp":1781246278595,"version":"3.54.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.schres.2012.10.023","type":"journal-article","created":{"date-parts":[[2012,11,29]],"date-time":"2012-11-29T18:49:29Z","timestamp":1354214969000},"page":"18-24","source":"Crossref","is-referenced-by-count":52,"title":["Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: A randomized double-blind study"],"prefix":"10.1016","volume":"143","author":[{"given":"Robert C.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Bark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anantha","family":"Shekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sauburah","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Mortiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2012.10.023_bb0010","doi-asserted-by":"crossref","first-page":"s202","DOI":"10.2337\/dc11-s221","article-title":"Type 2 diabetes can be prevented with early pharmacological intervention","volume":"34","author":"DeFronzo","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.schres.2012.10.023_bb0015","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2012.10.023_bb0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.jcp.0000264993.86029.30","article-title":"Treatment of antipsychotic-associated hyperglycemia with pioglitazone: a case series","volume":"27","author":"Edlinger","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2012.10.023_bb0100","series-title":"nQuery Advisor: Version 3.0, User's Guide","author":"Elashoff","year":"1999"},{"key":"10.1016\/j.schres.2012.10.023_bb0030","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.2337\/dc07-0717","article-title":"Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)","volume":"30","author":"Erdmann","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.schres.2012.10.023_bb0035","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jacc.2006.12.048","article-title":"The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study","volume":"49","author":"Erdmann","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.schres.2012.10.023_bb0040","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1176\/ajp.156.12.1944","article-title":"Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity","volume":"156","author":"Gold","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.10.023_bb0045","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2012.10.023_bb0050","doi-asserted-by":"crossref","first-page":"619-619","DOI":"10.1176\/appi.ajp.2008.08081195","article-title":"Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome","volume":"166","author":"Kemp","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.10.023_bb0105","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jad.2011.06.033","article-title":"Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity","volume":"136","author":"Kemp","year":"2012","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.schres.2012.10.023_bb0060","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2012.10.023_bb0065","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0169-409X(02)00093-5","article-title":"Troglitazone: the discovery and development of a novel therapy for treatment of type 2 diabetes mellitus","volume":"54","author":"Parker","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.schres.2012.10.023_bb0070","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1586\/14779072.4.4.445","article-title":"Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects","volume":"4","author":"Pftzner","year":"2006","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.schres.2012.10.023_bb0005","series-title":"Vigil Continuous Performance Test","author":"Psychological Corporation","year":"1988"},{"key":"10.1016\/j.schres.2012.10.023_bb0075","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00125-005-0097-z","article-title":"The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)","volume":"49","author":"Ramachandran","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.schres.2012.10.023_bb0080","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.neurobiolaging.2009.10.009","article-title":"Efficacy of PPAR-gamma agonist pioglitazone in mild alzheimer disease","volume":"32","author":"Sato","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.schres.2012.10.023_bb0090","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4088\/JCP.08m04446yel","article-title":"Effects of olanzapine and risperidone on glucose metabolism and Insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study","volume":"70","author":"Smith","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2012.10.023_bb0085","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.schres.2010.04.001","article-title":"Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study","volume":"120","author":"Smith","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2012.10.023_bb0095","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/713782132","article-title":"Glitazones: clinical effects and molecular mechanisms","volume":"34","author":"Stumvoll","year":"2002","journal-title":"Ann. Med."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996412005956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996412005956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T07:13:46Z","timestamp":1687850026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996412005956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0920996412005956"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2012.10.023","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}